Ceribell, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 48/100
What the filing says
Ceribell, Inc. entered into a Credit, Security and Guaranty Agreement dated August 5, 2026 with MidCap Funding IV Trust (Agent) and lenders. The facility consists of: (1) Term Loans: $55M total ($30M Tranche 1, $25M Tranche 2, with Tranche 2 discretionary); (2) Revolving Credit: $20M base commitment, expandable to $30M via two $5M-$10M tranches if borrowing base and financial conditions are met. Interest rates: Term Loans at SOFR + 5.00%; Revolving at SOFR + 3.75%. Maturity: August 5, 2031. Security: first lien on substantially all assets including accounts receivable (85% advance rate) and inventory (40% advance rate). Borrowing base includes $20M floor through December 31, 2027. Financial covenants include minimum net revenue and unrestricted cash requirements, with testing triggered if total commitments exceed $35M.
Why this rating
Substantial financing ($75M committed) is 18% of $417M market cap—meaningful for growth/operations, but structures as standard asset-based lending, not transformational M&A or go-concern event. Positive signal for liquidity and runway; routine for mid-cap medtech.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.